Skip Navigation


NDT Advance Access originally published online on August 22, 2005
Nephrology Dialysis Transplantation 2005 20(11):2299-2301; doi:10.1093/ndt/gfi109
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/11/2299    most recent
gfi109v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gross, P.
Right arrow Articles by Palm, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, P.
Right arrow Articles by Palm, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Comment

Thiazides: do they kill?

Peter Gross and Catrin Palm

Nephrology, Medizinische Klinik III, Universitätsklinikum C.G. Carus, Dresden, Germany

Correspondence and offprint requests to: Peter Gross, Nephrology, MK III, Universitätsklinikum C.G. Carus, Fetscherstr. 74, D-01307 Dresden, Germany. Email: peter.gross@mailbox.tu-dresden.de

Keywords: aquaporin-2; hyponatraemia; thiazides

The first 10% of the full text of this article appears below.



   Introduction
 
In 2000 and 2002 after the ALLHAT-study had been published [1,2] there was a paradigm shift in the use of thiazides. ALLHAT was a study of cardiovascular endpoints in relation to different antihypertensive treatments in 33 357 hypertensive patients observed over an average of 4.9 years. The study [1,2] found no differences between the three treatment groups [diuretics in the form of chlorthalidone vs calcium antagonists (amlodipine) vs ACEI (lisinopril)]. Consequently, after ALLHAT, it was emphasized that thiazides ought to be an integral part of the hypertensive patient's prescription sooner or later—and health policy makers clearly favoured ‘sooner’ over ‘later’ because of their low cost. Indeed, the sale of thiazide-like agents has more than doubled between 2001 and 2004 in Germany alone. . . . [Full Text of this Article]



   Why is the lady comatose?
 


   Thiazide-hyponatraemia: do they die?
 


   What is wrong with summer?
 


   Any new kids on the block?
 


   Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?